<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Kremer Hovinga JA</dc:creator>
  <dc:creator>Coppo P</dc:creator>
  <dc:creator>Lämmle B</dc:creator>
  <dc:creator>Moake JL</dc:creator>
  <dc:creator>Miyata T</dc:creator>
  <dc:creator>Vanhoorelbeke K</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic anaemia and a variable degree of ischaemic organ damage, particularly affecting the brain, heart and kidneys. Acute TTP was almost universally fatal until the introduction of plasma therapy, which improved survival from &lt;10% to 80-90%. However, patients who survive an acute episode are at high risk of relapse and of long-term morbidity. A timely diagnosis is vital but challenging, as TTP shares symptoms and clinical presentation with numerous conditions, including, for example, haemolytic uraemic syndrome and other thrombotic microangiopathies. The underlying pathophysiology is a severe deficiency of the activity of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13), the protease that cleaves von Willebrand factor (vWF) multimeric strings. Ultra-large vWF strings remain uncleaved after endothelial cell secretion and anchorage, bind to platelets and form microthrombi, leading to the clinical manifestations of TTP. Congenital TTP (Upshaw-Schulman syndrome) is the result of homozygous or compound heterozygous mutations in ADAMTS13, whereas acquired TTP is an autoimmune disorder caused by circulating anti-ADAMTS13 autoantibodies, which inhibit the enzyme or increase its clearance. Consequently, immunosuppressive drugs, such as corticosteroids and often rituximab, supplement plasma exchange therapy in patients with acquired TTP.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/43924</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/nrdp.2017.20</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28382967</dc:relation>
  <dc:source>Nature reviews. Disease primers. - 2017</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">ADAMTS13 Protein</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Acetylcysteine</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Antiviral Agents</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Glucocorticoids</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">HIV Infections</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Immunologic Factors</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Immunomodulation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Pregnancy</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Pregnancy Complications</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Purpura, Thrombotic Thrombocytopenic</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Rituximab</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Shiga Toxins</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Splenectomy</dc:subject>
  <dc:title xmlns:ns16="xml" ns16:lang="en">Thrombotic thrombocytopenic purpura.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
